



12:00PM 2005.09.12 (GMT+1)

Ad hoc: Epigenomics AG announces resignation of Aron Braun

Berlin, Germany - September 15, 2005 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, today announced that effective October 31, 2005 Aron Braun, co-founder and COO of the company, will resign from the company's executive board due to personal reasons.

END OF AD HOC

"It is with great regret that we have accepted Aron's decision to pursue other opportunities in his home country Switzerland. We would like to thank him for his dedication to Epigenomics over the past seven years. His commitment to building the world's premier DNA methylation research and development operation, and designing industrialized processes making methylation possible on a large scale, have been an inspiration to everyone who has worked with him," noted Alex Olek, CEO of Epigenomics. "We wish him much happiness and success in his future endeavours."

"I have thoroughly enjoyed helping to start, build and grow Epigenomics from its Berlin back-yard roots in 1998 to the Trans-Atlantic operation it is today, employing multiple teams committed to improving people's lives," stated Aron Braun. "The products under development at Epigenomics could potentially have a great impact on the way that diseases such as cancer are diagnosed and ultimately treated. I am extremely pleased to have been part of such pioneering medical innovation and will closely follow Epigenomics' future development."

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. By detecting and interpreting DNA methylation patterns, Epigenomics' tests can potentially diagnose disease at an early stage and help guide physicians to select an appropriate therapy. Epigenomics collaborates with Roche Diagnostics on the development of several diagnostic products in cancer. The company has its headquarters in Berlin, Germany, and a wholly owned subsidiary in Seattle, USA. For more information, please visit our website at www.epigenomics.com.

###

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Epigenomics AG
Hong Thieu (VP Corporate Affairs)
Oliver Schacht (CFO)
+49 30 24345 0

Halsin Partners
Mike Sinclair
+44 (0) 870 747 0880
Heike Heinrichs
+49 (0) 89 25 55 06 50